Literature DB >> 16206787

Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs in canine blood.

Heather K Streppa1, Chris J Jones, Steven C Budsberg.   

Abstract

OBJECTIVE: To evaluate cyclooxygenase (COX) selectivity of several nonsteroidal anti-inflammatory drugs (NSAID) in canine blood in vitro. ANIMALS: 11 healthy adult male hound crosses. PROCEDURE: 9 NSAID were studied at 5 concentrations. Thromboxane B2 (TxB2) was assayed as a measure of COX-1 activity in clotted blood. Prostaglandin E2 (PGE2) was assayed as a measure of COX-2 activity in heparinized, lipopolysaccharide (LPS)-stimulated blood. All assays were competitive ELISA tests. Cyclooxygenase selectivity was expressed as a ratio of the concentration of an NSAID that inhibited 50% of the activity (IC50) of COX-1 to the IC50 of COX-2. A separate ratio of the concentration that inhibited 80% of COX activity (IC80) was also determined. A ratio of < 1.0 indicated selectivity for COX-1, whereas a ratio of > 1.0 indicated COX-2 selectivity.
RESULTS: Ketoprofen, aspirin, and etodolac were COX-1 selective. Piroxicam, meloxicam, and carprofen had COX-2 selectivity. The IC50 and IC80 values were similar for most NSAID.
CONCLUSIONS: This methodology provides repeatable data from individual dogs and is comparable to results of previous in vitro and ex vivo models. Findings are also consistent with those of canine studies performed in vivo, suggesting that this is a viable in vitro assessment of the COX selectivity of NSAID in dogs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 16206787     DOI: 10.2460/ajvr.2002.63.91

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  8 in total

1.  Pharmacology of drugs used to treat osteoarthritis in veterinary practice.

Authors:  Peter Lees
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

2.  A randomized blind placebo-controlled trial investigating the effects of photobiomodulation therapy (PBMT) on canine elbow osteoarthritis.

Authors:  Andrea L Looney; Janice L Huntingford; Lauren L Blaeser; Sabine Mann
Journal:  Can Vet J       Date:  2018-09       Impact factor: 1.008

3.  Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy.

Authors:  Naoya Maekawa; Satoru Konnai; Yumie Asano; Yamato Sajiki; Tatsuya Deguchi; Tomohiro Okagawa; Kei Watari; Hiroto Takeuchi; Satoshi Takagi; Kenji Hosoya; Sangho Kim; Hiroshi Ohta; Yukinari Kato; Yasuhiko Suzuki; Shiro Murata; Kazuhiko Ohashi
Journal:  Sci Rep       Date:  2022-06-03       Impact factor: 4.996

4.  Platelet aggregation in rhesus macaques (Macaca mulatta) in response to short-term meloxicam administration.

Authors:  Keith E Anderson; Jamie Austin; Evelyn P Escobar; Larry Carbone
Journal:  J Am Assoc Lab Anim Sci       Date:  2013-09       Impact factor: 1.232

5.  Analgesic Efficacy of Firocoxib, a Selective Inhibitor of Cyclooxygenase 2, in a Mouse Model of Incisional Pain.

Authors:  Balagangadharreddy Reddyjarugu; Todd Pavek; Teresa Southard; Jason Barry; Bhupinder Singh
Journal:  J Am Assoc Lab Anim Sci       Date:  2015-07       Impact factor: 1.232

6.  Bioavailability and pharmacokinetics of oral meloxicam in llamas.

Authors:  Amanda J Kreuder; Johann F Coetzee; Larry W Wulf; Jennifer A Schleining; Butch KuKanich; Lori L Layman; Paul J Plummer
Journal:  BMC Vet Res       Date:  2012-06-21       Impact factor: 2.741

7.  Molecular analysis of the microbiota in hard feces from healthy rabbits (Oryctolagus cuniculus) medicated with long term oral meloxicam.

Authors:  David Eshar; J Scott Weese
Journal:  BMC Vet Res       Date:  2014-03-11       Impact factor: 2.741

8.  Meloxicam decreases the migration and invasion of CF41.Mg canine mammary carcinoma cells.

Authors:  María P Iturriaga; Rodolfo Paredes; Jose I Arias; Cristian G Torres
Journal:  Oncol Lett       Date:  2017-06-16       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.